ZSTK474 is primarily used in research and development within the field of oncology. It functions as a potent and selective inhibitor of PI3K (phosphoinositide 3-kinase), a key enzyme involved in cell growth, proliferation, and survival. By targeting the PI3K pathway, ZSTK474 has shown potential in inhibiting the growth of various cancer cells, particularly in preclinical studies. Its application is significant in exploring new therapeutic strategies for cancers that are driven by PI3K signaling abnormalities, such as breast, lung, and prostate cancers. Researchers are also investigating its potential in combination therapies to enhance the efficacy of existing cancer treatments.